Story thread · 2 reports / 2 sources

Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

biopharmadive.com · 5dShare

Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.”

First report: Tarsus bets $450M on Alkeus’ Stargardt drug — endpts.com, 5d